Science First – White paper

creos™ xenoprotect:strong native collagen membrane
High mechanical strength1– High suture retention– High tear resistance

Easy handling– Does not stick to instruments– Both sides can face defect– Low surface expansion when hydrated

Facilitates new bone formation2, 3– Significantly higher new bone formation in the central portion of the defect,in comparative in vivo study– Associated with significantly increased expression of growth factor BMP-2​

Schematic showing the defect height:

High success rate proven in
randomized controlled trial4
In an RCT published by Dr Istvan Urban et al., creos
xenoprotect and Geistlich Bio-Gide® similarly reduced defectheight after simultaneous GBR and implant placement.

High tensile strength and suture retention1
Studied in vitro compared to other collagen membranes– Showed the highest suture retention when hydrated (6.1 N)​– Demonstrated the highest force at break, wet (21.2 N)

Prior to treatment
4.9 ± 1.9 mm

1.0 ± 1.3 mm

1.7 ± 2.1 mm

creos™
xenoprotect

Referencecreos™
xenoprotect

Reference

Comparison of commercial membranes in a hydrated state876543210creos™ CO

Stable during the period requiredfor barrier function5
After 20 weeks in an animal model, the thickness of creos
xenoprotect decreased only slightly, whereas Geistlich
Bio-Gide® showed around 50% thickness loss.

6 months after GBR

5.1 ± 2.1 mm

JS

OFBG

BEMLOPBM

Sutureretention
wet [N]

Non-cross-linked collagen membranes (NXL) – creos™
xenoprotect [Nobel Biocare]; CO: Copios [Zimmer]; JS:Jason [botiss]; OF: Osseoguard Flex [3i]; BG: Bio-Gide[Geistlich]
Cross-linked collagen membranes (XL) – BE: BioMend
Extend [Zimmer]; ML: Mem-Lok [BioHorizons]; OP:
OssixPlus [Datum Dental]; BM: BioMend [Zimmer];*Statistically significant

Proprietary production process
Developed at Matricel, Nobel Biocare's manufacturing site forregenerative materials in Germany, more than 30 manufacturing processes were evaluated before choosing the process that
produced the best cell compatibility and mechanical strength.
Manufacturing site of creos xenoprotect

Clinical caseabcdefghijImages courtesy of Dr. B. Wessing, Germany

A 54-year-old male patient reported with missing teeth 46, 47. Poor bone quantity with 2-3 mm thickness at thecrest and 8 mm and 6 mm of residual bone, respectively, on top of the nervus alveolaris inferior region.
(a, b) Pre-operative assessment​(c) Cortical perforations and tenting screws applied​(d) creos xenoprotect and bone graft applied​(e) Graft immobilized - spanning of creos xenoprotect(f) Panoramic radiograph after GBR​(g) After 6 months: 3 mm vertical, 8 mm horizontalbone gain(h, i) Immediately after implant placement ​(j) Situation after four months' healing

Dr. Fabrizio Colombo ​Oral surgeon, Italy

Dr. Ignacio Ginebreda
Oral surgeon, Spain

Dr. Catherine Rivière
Periodontist, France“Strength and elasticity of creos
xenoprotect can protect andstabilize the grafted area even in
the most challenging cases.”“I choose creos xenoprotect for
my grafting procedures due toits exceptional handling andits track record of consistently
delivering predictable outcomes.”“I use creos xenoprotect combinedwith creos xenogain particularly
in cases of GBR. The membrane,stabilized by pins, offers significant
strength and stability.”More to explore

Scientificevidence

Clinical cases

Production &handling movie

1. Gasser A, et al. J Dent Res 2016,95(Spec Iss A): 1683 • 2. Wessing B, et al. Clin Oral Impl Res; 2017;28(11):e218-e226 • 3. Omar O,et al. Clin Oral Impl Res; 2018;29(1):7-19 • 4. Urban I, et al. Clin Oral Impl Res. 2019;30:487–497 • 5. Bozkurt A, et al. Clin Oral Impl Res;
2014;25(12):1403-1411. ​89043 EU 2311 © Nobel Biocare Services AG, 2023. All rights reserved. Distributed by: Nobel Biocare. Disclaimer: Nobel Biocare, theNobel Biocare logotype and all other trademarks are, if nothing else is stated or is evident from the context in a certain case,trademarks of Nobel Biocare. Please refer to nobelbiocare.com/trademarks for more information. Product images are notnecessarily to scale. All product images are for illustration purposes only and may not be an exact representation of the product.
Some products may not be regulatory cleared/released for sale in all markets. Please contact the local Nobel Biocare sales office forcurrent product assortment and availability. Caution: Federal (United States) law or the law in your jurisdiction may restrict thisdevice to sale by or on the order of a dentist or a physician. See Instructions For Use for full prescribing information, includingindications, contraindications, warnings and precautions. creos™ xenoprotect is manufactured by Matricel GmbH, Kaiserstrasse
100, 52134 Herzogenrath, Germany and distributed by Nobel Biocare Services AG. creos™ xenogain is manufactured by Nibec Co.
Ltd., Chungcheongbuk-do, 27816 Korea and distributed by Nobel Biocare Services AG.

Why creos
xenoprotect?